ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Mutational landscape and clinical implications of VHL in clear cell renal cell carcinoma: a multi-dataset analysis of 1377.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics.Biomarker research · 2026Review
- Human biomarker navigator.iMeta · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKidney cancer stands as a threat worldwide, with clear cell renal cell carcinoma (ccRCC) emerging as its predominant subtype. Through the establishment of extensive databases, the somatic mutations associated with ccRCC are successfully pinpointed. The tumor suppressor gene Von Hippel-Lindau (VHL) is commonly mutated in ccRCC.
objectiveIn this study, we aim to analyze different cBIOPortal datasets to explore VHL mutation frequencies in ccRCC.
methodsThe datasets explored were Kidney Renal Clear Cell Carcinoma (TCGA, Nature 2013), Kidney Renal Clear Cell Carcinoma (IRC, Nat Genet 2014), Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy), Kidney Renal Clear Cell Carcinoma (TCGA, PanCancer Atlas). Data mining from various datasets revealed that VHL is the most mutated gene, with mutation frequencies of 79.5%, 51.2%, 49.9%, and 41.3% across different datasets: Kidney Renal Clear Cell Carcinoma (IRC, Nat Genet 2014), Kidney Renal Clear Cell Carcinoma (TCGA, Nature 2013), Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy), and Kidney Renal Clear Cell Carcinoma (TCGA, PanCancer Atlas), respectively.
resultsThe mutated VHL gene is associated with significantly reduced overall survival (OS) rates based on the analyses of these datasets. VHL mutation becomes more advanced at a late age with many distant metastases.
conclusionThis data confirms the mutational burden of VHL in ccRCC and suggests it is a potential therapeutic target for the management of ccRCC.
Indexed as
Identifiers
40425983What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.